



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known		
				Application Number	10/551,004	
				Filing Date	September 26, 2005	
				First Named Inventor	Henning Walczak	
				Art Unit	1644	
Examiner Name	Unassigned J. Lockard					
Attorney Docket Number	045278-002000					
Sheet	1	of	B1	1		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
/J.L./	A1	US-6,015,559	01/18/2000	Lynch, et al.	

FOREIGN PATENT DOCUMENTS							
Examiner Initials ²	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴ Kind Code ⁵ (if known)				
J.L. ↓	B1	WO	02/090553	11/14/2002	Erfinder, et al.		
	B2	WO	02/079415	10/10/2002	Gillies		
	B3	WO	02/066514	08/29/2002	Gillies, et al.		
	B4	WO	01/49866	07/12/2001	Erfinder, et al.		
	B5	WO	01/41803 A1	06/14/2001	Erfinder, et al.		
	B6	EP	0 992 243	04/12/2000	Nagata, et al.		
	B7	WO	00/18932	04/06/2000	Stahl, et al.		
	B8	EP	0 965 637	12/22/1999	Nakamura, et al.		
	B9	WO	99/50413	10/07/1999	Bumol, et al.		
	B10	WO	98/36768	08/27/1998	Grooten, et al.		
	B11	WO	95/27735	10/19/1995	Krammer, et al.		
J.L.	B12	EP	0 526 452	02/10/1993	Canon, et al.		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/J.L./ ↓	C1	DEMJEN, D <i>et al.</i> , "Neutralization of CD95 ligand promotes regeneration and functional recovery after spinal cord injury", <i>Nat. Med</i> 10(4):389-395, 2004.	
	C2	KIM, Yon Su <i>et al.</i> , "Targeting the IL-15 Receptor with an Antagonist IL-15 Mutant/Fc 2a Protein Blocks Delayed-Type Hypersensitivity", <i>J. Immunol</i> 160:5742-5748, 1998.	
	C3	MARTIN-VILLALBA, A. <i>et al.</i> , "Therapeutic neutralization of CD95-ligand and TNF attenuates brain damage in stroke", <i>Cell Death Differ.</i> 8(7):679-686, 2001.	
	C4	SMITH, CA <i>et al.</i> , "CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family cytokines with homology to TNF", <i>Cell</i> 73(7):1349-1360, 1993	

Examiner Signature	/Jon Lockard/	Date Considered	12/03/2010
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at 222.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.